Temsirolimus in women with platinum-resistant ovarian cancer or advanced/recurrent endometrial cancer: a multicenter phase II trial of the AGO Study Group (AGO-GYN 8)
F Hilpert, C Kurzeder, B Schmalfeldt, P Neuser, N de Gregorio, J Pfisterer, TW Park-Simon, S Mahner, W Schröder, HJ Lück, M Heubner, L Hanker, F Thiel, G Emons · Geburtshilfe und Frauenheilkunde · 2014 · Heft 09
Bibliografische Angaben
Zusammenfassung
Background: Inhibition of mTOR with temsirolimus (T) might be an efficacious treatment of patients with epithelial ovarian cancer (OC) or endometrial cancer (EC). Methods: Patients (pts) with platinum and taxane resistant OC (n = 22) or with advanced/recurrent EC, who had not received previous chemotherapy (n = 22) were treated with weekly IV infusions of T (25 mg). Primary endpoint was progression free survival after 4 months (OC) or 6 months (EC). A two stage design was used with second stage of accrual if < 10 of the first 22 pts (OC) or < 7 of the first 22 pts (EC) had progressive disease after the first 8 w…
